Experimental drug by Threshold Pharma has shown good results against Pancreatic cancer

Threshold pharmaceuticals Inc. has announced on Tuesday that the company's experimental drug, TH-302, against Pancreatic cancer has achieved better results in Phase 2b clinical results.

The company has reported that the progression free survival has increased in the patients in which the drug is used along with chemotherapy.

With the results of this trial, we are again very encouraged that TH-302 is conferring benefit to patients with aggressive and difficult to treat cancers," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "We look forward to its ongoing development with our partner Merck KGaA in this and other indications."

Source:
SayPeople

Via:
Threshold Pharmaceuticals